NTD ConnectOR

Welcome to NTD ConnectOR, formerly known as the Operational Research (OR) Inventory. This resource serves as a hub for researchers, funders and program implementers involved in OR.

Click the buttons below to enter new studies, search for existing studies or sign up to be notified of new studies matching your interests. For helpful resources on NTD ConnectOR, click here.


Recently added


1. Can the O-150 LAMP assay be established on whole blood? 2. Can the O-150 qPCR methodology be adapted for human sampling?


1. How does the performance of the O-150 LAMP compare to the O-150 qPCR assay?

2. What threshold be used to define positive vs negative results for both assays?

3. Can deep sequencing reveal over potential biomarkers for further investigation?

Countries Cameroon
Diseases: Onchocerciasis

  • An Ov16/OVOC3261 biplex IgG4 test, whereby we are confident that we can provide > 60% sensitivity and 99.8% specificity, as required by the TPP for Onchocerciasis Elimination Mapping.
  • Demonstration that the Ov16/OVOC3261 biplex IgG4 test behaves at least as good with blood as with plasma/serum samples (notably a perceived weakness of the SD Ov16 RDT)

Diseases: Onchocerciasis

The overall goal of this research proposal is to prioritize the five novel Bancroftian antigen candidates with respect to their ease-of-use and practicability within the frame of a future Wb123/WbAgx biplex test, based on their biophysical properties, stability data and behavior in our lateral flow assay setup. Along with the concurrent biochemical/clinical validation by the Nutman group. This will allow an informed choice as to which candidate antigen(s) should be used for the biplex assay development.